PFIZER.NS Pfizer Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 26865 | 17478 | 65.06% |
| 2026-08-27 | 20922 | 11378 | 54.38% |
| 2026-08-26 | 26447 | 13316 | 50.35% |
| 2026-08-25 | 24870 | 14188 | 57.05% |
| 2026-08-24 | 20411 | 9748 | 47.76% |
| 2026-08-21 | 63975 | 26151 | 40.88% |
| 2026-08-20 | 297497 | 257747 | 86.64% |
| 2026-08-19 | 160066 | 111827 | 69.86% |
| 2026-08-18 | 76326 | 54820 | 71.82% |
| 2026-08-17 | 54880 | 35429 | 64.56% |
| 2026-08-14 | 11698 | 6247 | 53.40% |
| 2026-08-13 | 16223 | 9505 | 58.59% |
| 2026-08-12 | 148835 | 46710 | 31.38% |
| 2026-08-11 | 30220 | 21202 | 70.16% |
| 2026-08-10 | 51744 | 41486 | 80.18% |
| 2026-08-07 | 5857 | 2654 | 45.31% |
| 2026-08-06 | 16772 | 10291 | 61.36% |
| 2026-08-05 | 18332 | 11594 | 63.24% |
| 2026-08-04 | 29850 | 17769 | 59.53% |
| 2026-08-03 | 44131 | 29621 | 67.12% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers PFIZER.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 04 May 2020 | Anil Gupta | Employees/Designated Employees | Buy | Market Purchase | 125 | 514500 | 0.00% | XBRL |
| 04 May 2020 | Anil Gupta | Employees/Designated Employees | Buy | Market Purchase | 25 | 101951 | 0.00% | XBRL |
| 04 May 2020 | Anil Gupta | Employees/Designated Employees | Sell | Market Sale | 150 | 659000 | 0.00% | XBRL |
| 04 May 2020 | Anil Gupta | Employees/Designated Employees | Buy | Market Purchase | 100 | 405000 | 0.00% | XBRL |
| 04 May 2020 | Anil Gupta | Employees/Designated Employees | Buy | Market Purchase | 25 | 105000 | 0.00% | XBRL |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers PFIZER.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
Needs net profit and CFO for 3+ stored years; only 0 on file.
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q3 FY2023-24 | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹539.97 Cr. | ₹546.63 Cr. | ₹562.86 Cr. | ₹588.59 Cr. | ₹537.99 Cr. | ₹603.05 Cr. | ₹642.34 Cr. | ₹645.03 Cr. | ₹629.23 Cr. | ₹653.17 Cr. | RevenueFromOperations |
| Net Profit | ₹129.98 Cr. | ₹178.86 Cr. | ₹150.71 Cr. | ₹158.35 Cr. | ₹127.60 Cr. | ₹191.75 Cr. | ₹189.02 Cr. | ₹141.84 Cr. | ₹199.82 Cr. | ₹204.47 Cr. | ProfitLossForPeriod |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers PFIZER.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitLossForPeriod | 7224300000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 45750000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 38032200000.0 |
| CurrentLiabilities | 6274800000.0 |
| EquityAttributableToOwnersOfParent | 42029000000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 25000000.0 |